

# MUSHROOMS INC. UPDATES

## January 2024



Mushrooms Inc 1Month Chart

### Corporate Structure and Shareholder Confidence:

Mushrooms Inc. has not issued any additional stock since September of 2023. We maintain a strong share structure, reflective of our commitment to company growth and shareholder value. Our financial health is robust, with no debt on our books, positioning us to react positively to our current developments and market opportunities.

**Outstanding Shares:**  
39,435,760

**Restricted:** 31,130,303

**Unrestricted:** 8,305,457

As with all public companies, we do anticipate periodic share depositing into the open market from legacy shareholders. I want to assure you that this should not be interpreted as a lack of faith in our endeavors. People have been paid for their contributions with stock allocation, and as I have seen, these are affiliate shareholders with limitations to what they can deposit each quarter.



Bacterial detection (for E-Coli, MRSA and more) using color change, allows for early diagnosis, treatment and visual monitoring of treatment effectiveness

Mycelium derived sutures show an increase in the speed of healing – we add color change in reaction to bacterial detection.

Nutrient and drug delivery in a textile that increases the speed of healing and detects bacterial growth.

## MEDICAL MYCELLIUS

The medical version of Mycellius revolutionizes medical textiles, bandages, and sutures through its multifaceted prowess. It offers antimicrobial potency, real-time bacterial detection, controlled drug delivery, and enhanced healing agency.

This innovation stands as a transformative force in infection control, wound healing and patient well-being, promising a paradigm shift in medical technology.

The use of this product spans medical, military and space travel. We see our Medical Mycellius having use for burn victims, as well as whole body wellness treatments of the future.

### Highlights on Bandage Technology:

In our quest to combat the global health threat posed by harmful bacteria and antimicrobial resistance (AMR), we have reached pivotal milestones that I would like to reiterate:

- Our full-utility-patent filed in October 2023 details innovative methods for bacterial detection, growth inhibition, and nutrient delivery, focusing on the development of multifunctional mycelium products such as thread, foam, films, gels, and liquids.
- We are addressing the increasing E. coli and MRSA threats in healthcare settings. The escalating crisis of antibiotic-resistant infections, with AMR responsible for 1.27 million global deaths in 2019 and projected to cause up to 10 million deaths annually by 2050, heightens the need for our advanced solutions.
- Our bandages, incorporating enzyme substrates, facilitate the rapid detection of bacterial enzymes, essential for immediate medical intervention. This real-time detection capability is a game-changer in the industry.
- The versatility of our bandages allows for a customized approach to a range of bacteria, including E. coli and MRSA, equipping medical professionals to effectively manage and anticipate new outbreaks.
- Our scientists have created a bacterial detection film for E. coli using chitin. The development of a prototype from chitosan for Phase 1 is progressing.
- We are actively discussing collaborations with a university partner, which could save us substantial costs while leveraging years of specialized expertise for our bandage development.



## Shareholder Queries and Responses:

### Investment and Funding Efforts:

Despite a challenging economic climate, our investor conversations are ongoing, with promising prospects for equity funding. To reduce dilution we are offering a 5x return on investment from sales at 30% of net. We are also exploring a mix of stock and equity options, excluding convertible notes.

### Product Development and Commercialization:

Our focus is laser-sharp on the bandage technology. The launch of this product is pivotal to supporting our Phase 2 suture development and Phase 3 textiles.

Nutraceutical testing has commenced, with 1000 units of each product ready for sale and feedback, paving the way for a full production run and transdermal delivery product development.

### Acquisitions and Market Expansion:

We continue discussions with mushroom growers for potential acquisitions. Shaping these acquisitions to be appealing and reassuring for growers is a priority and an ongoing process.

### Marketing and Promotion:

We are ramping up marketing efforts with exciting video content and reviews to enhance company awareness and education.

Rest assured, every step we take is with the intention of enhancing shareholder value and advancing our mission to revolutionize healthcare with sustainable, innovative solutions.

Thank you for your unwavering support. Your belief in our mission fuels our progress, and together, we will continue to strive for a healthier, more sustainable future.